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Abstract

*Correspondence to:

Systematic inflammatory response after spinal cord injury (SCI) is one of the factors leading to lesion development and a profound degree of functional loss. Anti-inflammatory compounds, such as curcumin and
epigallocatechin gallate (EGCG) are known for their neuroprotective effects. In this study, we investigated
the effect of combined therapy of curcumin and EGCG in a rat model of acute SCI induced by balloon
compression. Immediately after SCI, rats received curcumin, EGCG, curcumin + EGCG or saline [daily
intraperitoneal doses (curcumin, 6 mg/kg; EGCG 17 mg/kg)] and weekly intramuscular doses (curcumin,
60 mg/kg; EGCG 17 mg/kg)] for 28 days. Rats were evaluated using behavioral tests (the Basso, Beattie, and
Bresnahan (BBB) open-field locomotor test, flat beam test). Spinal cord tissue was analyzed using histological methods (Luxol Blue-cresyl violet staining) and immunohistochemistry (anti-glial fibrillary acidic
protein, anti-growth associated protein 43). Cytokine levels (interleukin-1β, interleukin-4, interleukin-2,
interleukin-6, macrophage inflammatory protein 1-alpha, and RANTES) were measured using Luminex
assay. Quantitative polymerase chain reaction was performed to determine the relative expression of genes
(Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, NfκB, Cntf) related to regenerative processes in injured spinal cord. We found that all treatments displayed significant behavioral recovery, with no obvious
synergistic effect after combined therapy of curcumin and ECGC. Curcumin and EGCG alone or in combination increased axonal sprouting, decreased glial scar formation, and altered the levels of macrophage
inflammatory protein 1-alpha, interleukin-1β, interleukin-4 and interleukin-6 cytokines. These results
imply that although the expected synergistic response of this combined therapy was less obvious, aspects of
tissue regeneration and immune responses in severe SCI were evident.

Pavla Jendelova, Ph.D. or
Meena Jhanwar-Uniyal, M.D.,
Ph.D., jendel@biomed.cas.cz or
meena_jhanwar@NYMC.edu.
#These authors contributed
equally to this work.
orcid:
0000-0002-4644-9212
(Pavla Jendelova);
0000-0002-0581-0972
(Meena Jhanwar-Uniyal)
doi: 10.4103/1673-5374.224379
Accepted: 2017-11-13

Key Words: spinal cord injury; epigallocatechin gallate; curcumin; inflammatory response; neural regeneration

Introduction
Spinal cord injury (SCI) is one of the most common causes
of death and paralysis worldwide. The primary insult results
in neuronal cell death, which is followed by a cascade of
events. These include the release of excitotoxic glutamate,
activation of microglia, death of oligodendrocytes and glial
scar formation (Dubendorf, 1999; Witiw and Fehlings, 2015).
One of the factors leading to worsening of the injury is the
immune response after the initial insult, resulting in a release
of pro-inflammatory cytokines, which trigger the secondary
processes. Influencing the early immune response after SCI
may decelerate the cavity formation processes, thus resulting
in the preservation of spinal tracts and decreased locomotor
deficits after SCI (Gal et al., 2009; Mietto et al., 2015).
Curcumin
(1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6heptadiene-3,5-dione) is a well-known anti-inflammatory
agent that is isolated from curcuma longa. It is also known
for its neuroprotective features and has been studied as an
effective therapeutic agent in experimental models of SCI
(Ormond et al., 2012; Sanli et al., 2012). Curcumin application after SCI or TBI results in a suppressed inflammatory

response via the TLR4-MyD88-NFκB dependent pathway,
which in turn attenuates the microglial activation and neuronal apoptosis after injury (Zhu et al., 2014; Ni et al., 2015).
The nuclear factor kappaB (NF-κB) pathway shows a strong
correlation with tumor necrosis factor-alpha (TNF-α) and
interleukin-1 (IL-1) levels after injury (Yuan et al., 2015).
Additionally, the impact of curcumin on the Stat-3 and NFκB pathway strongly influenced nitric oxide (NO) levels and
the reduction of astrogliosis after SCI (Wang et al., 2014;
Machova Urdzikova et al., 2015; Gokce et al., 2016; Sanivarapu et al., 2016). Following curcumin application, increased
behavioral recovery after SCI was observed (Ormond et al.,
2012; Zu et al., 2014; Machova Urdzikova et al., 2015). Moreover, curcumin displayed a role in decreased neuropathic
pain via antagonizing TRPV1 channels (Lee et al., 2013).
Epigallocatechin gallate (EGCG) is an active compound
from green tea which is also known for its anti-inflammatory potential and neuroprotective features (Khalatbary
and Ahmadvand, 2011). In a model of Alzheimer’s disease,
EGCG can elevate alpha secretase activity and enhance hydrolysis of the TNF-α-converting enzyme, and thus promote
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the cleavage of α-c terminal fragment of APP (Rezai-Zadech
et al 2005). The application of EGCG after SCI decreased
the level of TNF-α and IL-1, major players in inflammatory
response after SCI, and consecutively also decreased levels
of inducible nitric oxide synthase, cyclooxygenase-2, and
myelin peroxidase. The application of EGCG showed an
anti-apoptotic effect by decreasing the levels of Bax gene
expression and immunohistochemical positivity on tunnel
staining, and increasing expression levels of Bcl2, Bdnf and
Gdnf genes (Khalatbary et al., 2010; Tian et al., 2013). We
reported that EGCG decreases the nuclear translocation of
subunit p65 (RelA) of the NF-κB dimer, and therefore
attenuates the canonical NF-κB pathway (Urdzikova et al.,
2017). In several studies, EGCG administration after neural
damage led to a reduction of neuropathic pain (Kuang et al.,
2012; Xifro et al., 2015). Furthermore, several studies have
shown the effect of EGCG on edema, tissue protection, and
functional recovery after SCI (Khalatbary et al., 2010; Ge et
al., 2013). Despite that, all the mechanisms of action of these
compounds are unknown. Curcumin (Aydin et al., 2014;
Garcia-Nino et al., 2015; Liu et al., 2017) and EGCG (Dudka
et al., 2005; Meng et al., 2007) are used for their anti-oxidative, chelating and immunomodulating properties in various
diseases. In these therapies, TNF-α and IL-1 level reduction
is one of the key factors in their pro-regenerative features
after SCI (Khalatbary and Ahmadvand, 2011; Yuan et al.,
2015) and may result in a synergistic effect of curcumin and
EGCG. So far, a combination of both drugs is used as a complementary therapy in experimental cancer therapy (Yunos
et al., 2011; Eom et al., 2015).
In this study, the effect of the combined therapy of curcumin with EGCG in a balloon compression model of acute
SCI in rats was evaluated. White and grey matter tissue sparing, axonal sprouting, astrogliosis, the expression of genes
related to regenerative processes, immunomodulation, and
behavioral recovery after SCI were assessed.

Materials and Methods

Animals
Ten-week-old male Wistar rats (n = 131; AnLab, Prague,
Czech Republic), weighing 300 ±15 g, were used in this
study. The animals were housed in pairs in individually ventilated cage systems (Techniplast), with food and water ad
libidum. Animals were separated prior to the injury into the
two major groups: a behavioral group and a cytokine group.
Immediately after SCI, all animals from the behavioral group
were randomly divided into four subgroups for behavioral
examinations: saline (n = 10), curcumin (n = 13), EGCG
(n= 19) and curcumin + EGCG (n = 9). These animals were
also used for histological, immunohistochemical (n = 5/
group) and qPCR analysis after behavioral examinations (n
= 4/group). Animals in the cytokine group consisted of 20
rats per subgroup (saline, curcumin, EGCG, and curcumin
+ EGCG), which were sacrificed at different time points (n
= 5/group per time point: 1, 3, 7 and 10 days) after injury
and were evaluated for the levels of selected cytokines. All
experiments were performed in accordance with the European Communities Council Directive of 22 September 2010
(2010/63/EU) regarding the use of animals in research, and
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were approved by the Ethics Committee of the Institute of
Experimental Medicine, Academy of Sciences of the Czech
Republic (approval number: 277/2011 and 53/2014).
SCI induction and treatment
A lesion was created via a balloon-induced spinal cord
compression as previously detailed (Vanicky et al., 2001;
Urdzikova et al., 2006). This model was chosen for its relevance to closed injuries, with vertebrate body and arch
preserved, leading to a higher validity of local immune response after SCI. Briefly, approximately one centimeter of a
2-French Fogarty catheter (Edwards, Irvine, CA, USA) was
inserted into the epidural space through a laminectomy at
T10, aligned with the midline of the spinal cord and inflated
for 5 minutes. The volume of the inflated balloon was adjusted to 15 μL and the function was carefully checked in
every animal. Immediately after SCI, rats received daily (for
28 days after SCI) intraperitoneal doses of curcumin (Sigma-Aldrich, St. Louis, MO, USA; 6 mg/kg, diluted in olive
oil), EGCG (Sigma-Aldrich, 17 mg/kg, diluted in PBS), or
their combination, and weekly intramuscular injection (1,
7, 14, 21 and 28 days post-SCI, surrounding lesion area)
of curcumin (60 mg/kg in olive oil (Ormond et al. 2014),
Sigma), EGCG (17 mg/kg, diluted in PBS (Tian et al., 2013;
Renno et al., 2015), or a combination of both drugs.
Behavioral test
The Basso, Beattie, and Bresnahan (BBB) open-field
locomotor test
Basic locomotor function was evaluated using the BBB openfield locomotor test (Basso et al., 1995). Rats were placed in
an open field area for approximately four minutes every week
starting seven days after SCI. Animals were scored by two
independent examiners according to the BBB scale (0–21).
The scale 0–4 points reflect no or only small movement of
hindlimbs with no weight support; scale 5–8 points indicate
larger extent of movement with no weight support; scale 9–14
points suggest increasing frequency of weight-supported steps
and hindlimb coordination; scale 15–18 points reflect precise
movements such as specific paw placement rotation; scale 18–
20 points indicate tail balance and trunk stability; and scale 21
points indicate healthy animals. Hindlimbs scored separately,
and then an average value per animal was calculated.
Flat beam test
To evaluate advanced locomotor skills of injured animals,
such as weight support and hindlimb coordination, the flat
beam test was used (Goldstein, 1997). The latency (in seconds) and trajectory of animals crossing the beam was recorded and evaluated. Additionally, the rats were scored according to the modified version of the Goldstein scale (0–7)
(Goldstein, 1997). The flat beam test measures the ability to
balance on the beam (scale points 0–2), attempts of crossing the beam (scale points 2–3) and the frequency of using
hindlimbs for the task, technique of hindlimb coordination
and the gait (scale points 4–7). Time score reflects the time
that each rat needs to start performing the task (maximum
is 60 seconds). After a pre-training session, animals were
assessed twice a day for 3 consecutive days, and weekly from
the third week after injury.
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Plantar test
To evaluate the presence of hyperalgesia to thermal nociceptive stimulus, an Ugo Basile test apparatus (Ugo Basile,
Comercio, Italy) was used as previously described (Carstens
and Ansley, 1993). A radiant thermal stimulus was applied
to the plantar surface of the paws, and the latency (seconds)
of the paw withdrawal response was measured.
Tissue processing, histology and immunohistochemistry
To analyze the effect of curcumin, EGCG, or the combined
therapy on injured spinal cords, fifteen cross-sections (5 μm
thickness) per animal were selected at 1-mm intervals along
the cranio-caudal axis, including the lesion center. Cresyl
violet-Luxol fast blue staining was used to distinguish the
white and grey matter (WM/GM) of the injured spinal cord.
The total volume and distribution of spared white matter/
grey matter and cavity size were analyzed using ImageJ
software (NIH, Bethesda, MD, USA) (Additional Figure
1A, data are expressed as a percentage to the saline group
(100%)). For immunohistochemical analysis of axonal
sprouting, the antibody against Gap43 (Millipore, Billerica,
MA; 1:2000, overnight 4°C) was used. To visualize primary
antibody reactivity, goat anti-mouse IgG conjugated with
Alexa-Fluor 488 (Molecular Probes, Eugene, OR, USA; 1:200,
2 hours 4°C) was applied. The number of Gap43-positive
fibers per slide was counted using Tissue FAXS software
(Tissue Gnostics, Vienna, Austria) across the whole area
of the section (Additional Figure 1B). The results are displayed as the average number of GAP43-positive fibers per
slide in percentage, when compared to the saline group
(set to 100%). To determine the effect of treatment on glial scar formation, antibody against glial fibrillary acidic
protein (GFAP) (mouse anti-GFAP-Cy3; Sigma, St. Louis,
MO, USA; 1:300, overnight 4°C) was used. The thickness of
GFAP+ glial scar (the square area of GFAP-positive signal
of high density, directly surrounding the main lesion cavity;
data are expressed as a percentage per total section area) and
the number of protoplasmic astrocytes were analyzed using
ImageJ software (Additional Figure 1C). Histological and
immunohistochemical images were analyzed and quantified
using Aioskop 2 plus microscope (Zeiss, Oberkochen, Germany), LEICACTR6500 microscope (Leica Microsystems,
Milton Keynes, UK) and TissueFAXS and ImageJ software.
Quantitative reverse transcription-PCR (qRT-PCR)
To study the relative expression of rat genes related to regenerative processes after SCI, qRT-PCR was applied (Heid
et al., 1996).
RNA was isolated from parafomadehyde-fixed spinal cord
tissue sections using High Pure RNA Paraffin Kit (Roche,
Penzberg, Germany) (Bibikova et al., 2004; Streubel et al.,
2005). To quantify the amount of RNA, a spectrophotometer
(NanoPhotometerTM P-Class, Munchen, Germany) was used.
The isolated RNA was then reverse transcribed into cDNA,
using Transcriptor Universal cDNA Master (Roche, Penzberg,
Germany), and a thermal cycler [T100™ Thermal Cycler (BioRad, Hercules, CA, USA)]. cDNA solution, FastStart Universal Probe Master (Roche, Penzberg, Germany) and TaqMan®
Gene Expression Assays genes (Gapdh/Rn01775763_g1
(housekeeping gene), Sort1 (Nt3) /Rn01521847_m1, Olig2/

Rn01767116_m1, Fgf2/Rn00570809_m1, Gfap/Rn00566603_
m1, Gap43/Rn01474579_m1, Vegf/Rn01511601_m1, Casp3/
Rn00563902_m1, Cntf/Rn00755092_m1,Irf5/Rn01500522_
m1, Mrc1/Rn01487342_m1, and Life Technologies, Carlsbad,
CA, USA) were used to perform PCR.
The final volume of 10 μL, containing 25 ng of extracted
RNA was amplified by a real-time PCR cycler (StepOnePlus™, Life Technologies, Carlsbad, CA, USA). All amplifications were run under the same cycling conditions (2
minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles
of 15 seconds at 95°C and 1 minute at 60°C). A negative
control was included in each array. Tested samples were run
in duplicates, and to determine the relative quantification
of gene expression, the ∆∆Ct method was applied (Pfaffl,
2001). Data were analyzed by StepOnePlus® software (Life
Technologies, Carlsbad, CA, USA). The gene expression levels were normalized using Gapdh as a reference gene, and all
data are related to the values of SCI rats treated with vehicle.
A log2 scale was used to display the symmetric magnitude
for up and down regulated genes.
Luminex assay
In order to evaluate the effect of anti-inflammatory drugs
(curcumin, EGCG and combined therapy) on levels of cytokines after SCI, Luminex assay was applied (Urdzikova
et al., 2014). On the 1st, 3rd, 7th and 10th days after SCI, the
samples of injured spinal cord were taken, and incubated in
cell culture media (24 hours, DMEM (Sigma), supplemented
with 10% fetal bovine serum and 0.2% primocin). The levels
of cytokines (six-plexbead assay for interleukin-1β (IL-1β),
interleukin-4 (IL-4), interleukin-2 (IL-2), interleukin-6 (IL6), macrophage inflammatory protein 1-alpha (MIP-1α),
and regulated on activation, normal T cell expressed and
secreted (RANTES); Millipore, Billerica, MA, USA) in the
media were detected using a customized Milliplex inflammatory cytokine kit and Magpix instrumentation software.
The raw data, consisting of mean fluorescence intensity, using a five-parameter logistic fit curve (standard curve) were
recalculated to the concentration of each cytokine (ng/μL).
Results are displayed as a percentage change from non-lesioned tissue (100%) for each time point.
Statistical analysis
Statistical evaluation was performed by SigmaStat software
(Sistat Software Inc., San Jose, CA, USA). To evaluate the
differences between treatment groups in behavioral study,
white/grey matter sparing, and glial scar formation, twoway repeated measures analysis of variance (ANOVA) was
used. For the evaluation of qPCR and luminex results, twoway ANOVA was applied. Axonal sprouting was evaluated
by one-way ANOVA. As a pair-to-pair post-hoc test, the Student-Newman-Keuls (SNK) test was chosen. Data in graphs
are represented as the mean ± SEM. Differences were considered statistically significant when P < 0.05. F values (ANOVA)
or q values (SNK test) are presented when P < 0.05.

Results

Behavioral recovery
BBB open-field locomotor test
Behavioral recovery after SCI was assessed by the BBB open121

Ruzicka J,UrdzikovaLM, SvobodovaB, AminAG,KarovaK, DubisovaJ,ZaviskovaK, KubinovaS, SchmidtM, Jhanwar-UniyalM, JendelovaP (2018)Doescombinedtherapyof
curcuminand epigallocatechingallatehavea synergisticneuroprotective effect againstspinal cord injury? Neural RegenRes13(1):119-127. doi:10.4103/1673-5374.224379.

field locomotor test. Results showed that behavioral recovery
of rats treated with saline only reached a plateau four weeks
after injury, with an average BBB score less than 6. Application of EGCG showed only mild improvement in locomotor
recovery observed in the BBB open-field locomotor test.
However, both curcumin and curcumin + EGCG treated
animals showed significantly higher recovery in comparison
with saline treated animals (Figure 1A) (two-way repeated
measures ANOVA F = 4.039, P < 0.05; SNK test: curcumin
vs. saline, q = 4.252, P < 0.05; curcumin + EGCG vs. saline,
q = 3.509, P < 0.05). Furthermore, the combined therapy
did not achieve a higher score than with application of curcumin only (SNK test: curcumin vs. saline: 1 week, q = 4.74,
P < 0.01; 2 weeks, q = 3.744, P < 0.05; 3 weeks, q= 4.549, P
< 0.05; 4 weeks, q = 3.789, P < 0.05; 5 weeks, q = 3.760, P <
0.05; 7 weeks, q = 4.147, P < 0.05; 9 weeks, q = 3.836, P < 0.05;
curcumin vs. EGCG: 2 weeks, q = 4.172, P < 0.05; 3 weeks,
q = 3.814, P < 0.05; 4 weeks, q = 3.682, P < 0.05; EGCG +
curcumin vs. saline: 3 weeks, q = 3.592, P < 0.05; 4 weeks, q
= 3.837, P < 0.05; 5 weeks, q = 3.900, P < 0.05; 7 weeks, q =
3.699, P < 0.05; 9 weeks, q = 3.906, P < 0.05; EGCG + curcumin vs. EGCG: 4 weeks, q = 3.694, P < 0.05).
Flat beam test
Advanced locomotor skills after SCI were evaluated by the
flat beam test. In this more physically demanding test, saline treated animals reached an average value of 1, which
represents the ability to balance on the beam for at least 30
seconds consecutively without being able to cross it. All treated groups reached values above two, which represents the
ability to cross at least half of the measured distance. Animals
treated with EGCG showed a significantly higher locomotor
score than saline treated animals (SNK test: EGCG vs. saline,
q = 3.594, P < 0.05). In the beginning, the combined curcumin and EGCG group showed higher scores than curcumin or
EGCG treated and saline treated animals. However, both
groups containing curcumin showed only a trend toward the
significance when compared to saline treated animals (SNK
test: curcumin vs. saline: q = 2.529, P = 0.08; curcumin +
EGCG vs. saline: q = 3.361, P = 0.096) (Figure 1B).
Simultaneously, the latency of flat beam crossing was measured (flat beam time score). The lowest latency in crossing
the beam was observed in the EGCG group (SNK test: saline
vs. EGCG: q = 4.343, P < 0.05; curcumin vs. EGCG, q = 3.828,
P < 0.05). The latency in crossing the beam in the curcumin +
EGCG group was lower than that in the EGCG group, however, there was no synergistic effect of the combined therapy
(Figure 1C) (SNK test: EGCG vs. saline: 7 weeks, q = 4.364,
P < 0.01; 8 weeks, q = 4.352, P < 0.05; 9 weeks, q = 3.874, P <
0.05; curcumin vs. saline, 7 weeks, q = 2.922, P < 0.05; EGCG
+ curcumin vs. saline, 7 weeks, q = 3.679, P < 0.05).
Plantar test
To estimate the effect of curcumin, EGCG and their combination on latency of response to nociceptive thermal
stimulus, a plantar test apparatus was used. No increased
hyperalgesia in response to nociceptive thermal stimulus
was observed in any of the treated animals (SNK test: saline
vs. curcumin, 1 week, q = 4.74, P < 0.05; 9 weeks, q = 4.088,
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P < 0.05; EGCG vs. curcumin, 1 week, q = 2.983, P < 0.05;
EGCG + curcumin vs. curcumin, 1 week, q = 3.685, P < 0.05,
9 weeks, q = 4.282, P < 0.05; EGCG + curcumin vs. EGCG, 2
weeks, q = 4.345, P < 0.05) (Figure 1D).
Histology and immunohistochemistry
White and grey matter
The effect of the combined therapy of curcumin and EGCG
on the preservation of spinal cord white (Figure 2A) and grey
matter (Figure 2B) was evaluated on a series of transverse
sections two months after SCI. None of the applied treatments showed a statistically significant effect on the preservation of injured spinal cord white and grey matter. Volume per
15 mm long analyzed spinal cord tissue was 23.1, 26.18, 25.98,
and 21.4 mm3 in the saline, EGCG, curcumin, and curcumin
+ EGCG groups, respectively (Figure 2G). Either curcumin
or EGCG application led to minor preservation of spinal cord
tissue after SCI. However, their combination had no positive
effect on tissue sparing (Figure 2A, B, G). On the contrary,
the combined therapy of curcumin and EGCG showed a
strong trend toward decreasing cavity size when compared to
the control saline treated animals (Figure 2F) (SNK test: gray
matter: EGCG vs. EGCG + curcumin, 3 cranial, q = 4.013, P
< 0.05; 2 cranial, q = 6.461, P < 0.001; 1 cranial, q = 4.865, P <
0.01; EGCG vs. saline, 2 cranial, q = 3.679, P < 0.05; 1 cranial,
q = 3.221, P < 0.05; EGCG vs. curcumin, 2 cranial, q = 2.967,
P < 0.05; 1 cranial, q = 4.556, P < 0.05; white matter: saline vs.
EGCG + curcumin, 2 cranial, q = 3.454, P < 0.05; EGCG vs.
EGCG + curcumin, 1 cranial, q = 4.302, P < 0.05; 2 cranial, q
= 5.372, P < 0.01; curcumin vs. EGCG + curcumin, 2 cranial,
q = 3.753, P < 0.05).
Astrogliosis
To detect the effect of the combined therapy of curcumin
and EGCG on glial scar formation, the area of GFAP+ scar
tissue (in%) on a series of transversal spinal cord sections
was measured two months after SCI. None of the single
treatment significantly reduced astrogliosis, however, the
number of protoplasmic astrocytes was reduced in both
curcumin and EGCG treated animals (Figure 2C, D). Combined therapy showed a partial decrease of GFAP+ scar
tissue area in the central region of the damaged spinal cord,
when compared to the saline group (two-way ANOVA; SNK
test: 1 caudal, P < 0.05, 2 caudal, P < 0.001). The number of
protoplasmic astrocytes was not changed in the curcumin
+ EGCG group (SNK test: glial scar: saline vs. curcumin,
2 caudal, q = 4.746, P < 0.01; saline vs. EGCG: 2 caudal, q
= 2.967, P < 0.05; saline vs. EGCG + curcumin, 1 caudal, q
= 4.206, P < 0.05, 2 caudal, q = 3.352, P < 0.05; EGCG vs.
curcumin, 2 caudal, q = 7.139, P < 0.001; EGCG vs. EGCG
+ curcumin, 2 caudal, q = 5.881, P < 0.001) (SNK test: saline
vs. curcumin, central, q = 4.230, P < 0.05, 1 caudal, q = 3.949,
P < 0.05; EGCG + curcumin vs. saline, 2 caudal, q = 3.867, P
< 0.05) (Figure 2C, D).
Axonal sprouting
The number of sprouting axons was measured using GAP43+
staining on a series of transversal spinal cord sections, two
months after injury. Both curcumin and EGCG compounds
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Figure 1 Locomotor and sensory recovery in rats following curcumin and epigallocatechin gallate (EGCG) application after spinal cord injury.
(A–C) The effect of curcumin, EGCG, and their combination on locomotor recovery after spinal cord injury was evaluated using the Basso, Beattie,
and Bresnahan (BBB) open-field locomotor test (A), flat beam test (B), and flat beam time score (C). Animals treated with combined therapy of
curcumin and EGCG, or curcumin alone, performed significantly better in the BBB open-field locomotor test than animals treated with saline. In
the flat beam test, EGCG treated animals showed the best recovery, followed by curcumin + EGCG treated animals. (D) The thermal nociception
was evaluated using the plantar test. No additional hyperalgesia was found after application of any of the used drugs. Two-way repeated measures
analysis of variance with the Student-Newman-Keuls post hoc test was used to determine statistical significance. *P < 0.05 (The color of asterisks
indicates the statistically different group(s)).
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Figure 2 Histological and immunohistochemical
analysis results of injured spinal cords.
The amount of spared white (A) and grey matter
(B) was determined 9 weeks after spinal cord injury
(SCI) in rats treated with saline, curcumin, EGCG,
or their combination. No statistically significant effect of applied drugs on tissue preservation was observed. In addition, the volume of white matter and
gray matter across the measured regions revealed
no significant difference (G). However, a strong
trend toward smaller cavity size was found (F).
The effect of the application of curcumin, EGCG,
or their combination on glial scar formation (C),
and the average number of protoplasmic astrocytes
per section (D) around the central lesion cavity
was measured 9 weeks after SCI. The combined
application of curcumin and EGCG had a suppressive effect on glial scar formation at the area of the
lesion epicenter. In the central region of the injury,
all treatments showed a positive effect on decreasing the number of protoplasmic astrocytes. The
distribution of the effect on X axis is measured as
distance in mm from the lesion center (set as 0) (A–
D). The effect of applied curcumin, EGCG, or their
combination on axonal sprouting. (E) The combination of curcumin and EGCG had a synergistic
effect on axonal sprouting, when compared to
saline treated animals. Two-way repeated measures
analysis of variance (ANOVA) with Student-Newman-Keuls test was used to determine statistical
significance (A–D). One-way ANOVA with Student-Newman-Keuls test was used to determine
the level of statistical significance (E–G). *P < 0.05
(the color of asterisk indicates the statistically different group(s)). Symbol of # is used when trend
toward significance has reached statistical value P
= 0.05–0.06. n = 5 per group.
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increased the number of GAP43+ fibers compared to saline
treated animals. This effect was enhanced in the combined
therapy, however, remained only as a strong trend toward
significance (Figure 2E) (one-way ANOVA: F = 2.723, P =
0.087; SNK test: q = 3.978, P = 0.057).
Endogenous gene response
The relative gene expression of several factors (Sort1, Fgf2,
Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, NfκB, Cntf)
related to regenerative processes was measured from injured spinal cord tissue two months after injury. Both curcumin and EGCG showed a similar pattern in expression
of targeted genes. The expression of most of the genes was
upregulated or unchanged in comparison with saline treated animals, with only Gfap downregulated. The combined
therapy showed opposite effects than each single treatment
in all targeted genes, except for Olig2 and Gfap. This pattern
was statistically significant in most cases when compared
with each single treatment (SNK test: EGCG + curcumin vs.
curcumin, Sort 1: q = 5.151, P < 0.01, FGF2 q = 4.1, P < 0.05,
Irf5: q = 3.71, P < 0.05; Mrc1: q = 4.238, P < 0.05; Casp3: q =
6.373, P < 0.01; Gap43: q = 4.965, P < 0.01; Cntf: q = 5.664, P
< 0.01; EGCG + curcumin vs. EGCG, Irf5: q = 5.386, P < 0.01;
Casp3: q = 4.023, P < 0.05; NFκB: q = 4.212, P < 0.05; Cntf: q
= 4.085, P < 0.05; saline vs. EGCG, Irf5: q = 4.059, P < 0.05;
saline vs. curcumin, Casp3, q = 4.160, P < 0.05) (Figure 3).
Inflammatory response
Changes in levels of cytokines (IL-1β, IL-4, IL-2, IL-6, MIP1α, and RANTES,) after SCI were measured. At specific
time points (1, 3, 7 and 10 days after injury), the effect of
curcumin, EGCG or their combination was evaluated. In the
curcumin + EGCG group, MIP-1α level was elevated for the
first three days compared to that in the saline, curcumin or
EGCG groups (1 day: two-way ANOVA, SNK test: P < 0.001,
details at the bottom of the paragraph). No other changes
were observed during this period. Seven days after injury,
in the treated animals, we observed decreased levels of IL4, IL-1β and IL-6 (two-way ANOVA, SNK test; curcumin
vs. curcumin + EGCG, P < 0.05), and the decreased level of
IL-6 persisted until day ten after injury. In the single treatment, curcumin initially decreased levels of IL-2 (two-way
ANOVA, SNK test: curcumin vs. curcumin + EGCG, P <
0.05), and RANTES (two-way ANOVA, SNK test; curcumin
+ EGCG vs. curcumin, P < 0.05; saline vs. curcumin, P < 0.05)
and increased the level of IL-6 (two-way ANOVA, SNK test:
curcumin vs. curcumin + EGCG, P < 0.05; curcumin vs.
EGCG, P < 0.05; curcumin vs. saline, P < 0.05; Figure 4). It
is important to note that there was a surge in MIP-1α level at
one day after injury in the curcumin + EGCG group, which
persisted through days three and seven after injury. MIP-1α
levels in the curcumin + EGCG group were reduced by day
10 after injury to levels in the curcumin or EGCG groups
(SNK test: EGCG + curcumin vs. saline, MIP-1α: day 1, q =
5.615, P < 0.001; RANTES: day 1, q = 3.930, P < 0.05; EGCG
+ curcumin vs. curcumin, MIP-1α, day 1, q = 7.750, P < 0.001;
IL-1β, day 1, q = 3.892, P < 0.05; IL-2, day 1, q = 4.505, P <
0.05; RANTES, day 1, q = 4.756, P < 0.05; EGCG + curcumin
vs. EGCG, MIP-1α, day 1, q = 6.039, P < 0.001).
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Discussion
In our study, the combined therapy for the treatment of
experimental SCI, using two anti-inflammatory compounds
curcumin and EGCG, had some positive effects on behavioral recovery, decreased glial scar formation, and supported
axonal sprouting. No spared white and grey matter was
observed. In addition, the combined therapy influenced
inflammatory response via regulating cytokine levels and
altered the gene expression of regenerative process-related
markers. The combined therapy did not exhibit synergistic effects compared to application of curcumin or EGCG
alone. No studies have been reported on the detailed information regarding the combined therapy of curcumin and
EGCG for the treatment of experimental SCI. An increasing
number of publications have been reported on the positive
effect of curcumin on an experimental model of SCI. An indirect impact of attenuated immune response may decrease
apoptosis, enhance axonal sprouting or modulate glial scar
formation, leading to behavioral recovery after SCI (Ormond
et al., 2012; Zu et al., 2014) or reducing neuropathic pain
(Lee et al., 2013). Curcumin influenced the regenerative
processes, in which the most commonly described is the
immunomodulatory effects, through the Jak/Stat3 and the
TLR4-MyD88-NFκB pathways (Wang et al., 2014; Machova
Urdzikova et al., 2015; Gokce et al., 2016). Immunomodulation by curcumin or EGCG inhibited the Jak/stat signaling
pathway, leading to reduction of glial scar formation (You et
al., 2017). The Jak/stat signaling pathway was also influenced
by the combined therapy of curcumin and EGCG (Figures
3, 4). Decreased NF-κB activity, along with reduced levels
of TNF-α and IL-1 and decreased expression of GFAP after
SCI was also reported after curcumin application (Yuan et
al., 2015). Application of EGCG after SCI not only promoted axonal sprouting (GAP-43 staining), but also increased
GFAP immunoreactivity (Renno et al., 2014; Renno et al.,
2015). In this study, we observed in vivo a trend towards an
increase in GAP-43 levels after combined therapy of curcumin and EGCG (Figure 2E). In our in vitro studies, we
tested the growth of neurites from adult dorsal root ganglia
(DRGs) in the presence of EGCG. We did not observe any
growth facilitation. However, EGCG reduced neuronal death
after application of H2O2 in hippocampal neuronal culture,
indicating a neuroprotective and anti-oxidative effect (data
not shown/unpublished data). The concentrations of EGCG
used in SCI studies vary from 10 to 50 mg/kg (Tian et al.,
2013; Renno et al., 2015; Urdzikova et al., 2017). In our previous study, we used a concentration within the lower range
to prevent a possible cytotoxic effect resulting from a high
concentration of EGCG, since it was reported that a high
concentration of EGCG (> 10 μM) can lead to increased
apoptosis and mitochondrial dysfunction in hippocampal
culture in vitro (Yin et al., 2009). Similarly to EGCG, curcumin can affect cell proliferation and survival and neurite
outgrowth in a dose dependent manner. Curcumin at high
concentration (above 10 μM) inhibited the proliferation and
survival of various types of cancer cells (Yang et al., 2017).
In PC12 cells, however, the in vitro application of curcuminoids at concentrations from 100 nM up to 20 μM has led
to a significant increase of neurite outgrowth through stim-
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ulating MAPK/ERK and PKC dependent pathways (Liao
et al., 2012; Dikmen, 2017). In addition, curcumin can act
through the Akt/GSK-3β dependent pathway and regulate
brain-derived neurotrophic factor level (Hoppe et al., 2013).
Curcumin also has a dose dependent effect on the neural
stem cells isolated from the subventricular zone of adult rats.
Curcumin at 500 nM supported neurosphere proliferation,
but at a higher concentration (μM), it resulted in widespread
apoptosis (Ormond et al., 2014). In this study, we also observed downregulated Gfap expression and decreased GFAP
staining intensity (Figures 2C and 3). However, the neuroprotective and antiapoptotic roles of curcumin and EGCG
lead to partial tissue sparing after SCI, which were not obCurcumin
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Figure 3 Gene expression changes in injured spinal cords after
application of curcumin, epigallocatechin gallate (EGCG) or their
combination.
Relative gene expression of factors related to the recovery process in
response to application of curcumin, EGCG or their combination 9
weeks after spinal cord injury. The expression level of saline treated
animals was set as zero value. One-way analysis of variance with Student-Newman-Keuls post hoc test was used to determine the level of
statistical significance. *P < 0.05(the color of asterisk indicates the statistically different group(s)). n = 4 per group.
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served in the combined therapy of curcumin and EGCG.
One important finding of this study is that the levels of
the chemokine MIP-1α increased dramatically one day after
injury, which persisted to days three and seven after injury.
MIP-1α has been implicated in cell adhesion and migration,
which might be required in the early phase after injury to
mobilize stem cells and astrocytes to the site of injury. Furthermore, recent observations have suggested that MIP-1α
is not only a chemokine, but also has a pivotal role in the
growth and survival of many cell types (Maurer and von Stebut, 2004; Terpos et al., 2005).
Moreover, the anti-oxidative effect of curcumin leads to an
increased level of super oxide dismutase (Sahin Kavakli et al.,
2011). Additionally, a dose dependent effect of curcumin on
stem cell proliferation has been reported (Son et al., 2014). It
is important to note that the combined therapy of curcumin
and neural stem cells has been successfully used in experimental SCI, showing that curcumin has the potential to support the paracrine effect of stem cells (Ormond et al., 2014).
EGCG, on the contrary, is studied much less in SCI. Studies have demonstrated that EGCG can affect neuropathic
pain (Xifro et al., 2015), tactile allodynia (Kuang et al., 2012)
and thermal hyperalgesia (Alvarez-Perez et al., 2015). In addition, EGCG has been shown to decrease pro-inflammatory
molecules, such as RhoA, FASN and TNF-α after SCI (Alvarez-Perez et al., 2015). EGCG has caused an improvement
in locomotor recovery after SCI, which was described due to
the positive impact on lipid peroxidation, neuronal apoptosis, and overall spinal cord tissue sparing (Khalatbary et al.,
2010; Tian et al., 2013). In this study, only mild improvement was observed on thermal hyperalgesia after application
of EGCG and curcumin (Figure 1D). EGCG exhibited an
anti-edema effect after SCI through downregulating AQP-4
and GFAP protein levels, suggesting a neuroprotective effect
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Figure 4 Effect of curcumin,
EGCG, or their combination
on cytokine levels in injured
spinal cords.
The levels of cytokines and
chemokines are presented after
application of curcumin, EGCG
or their combination at 1 (A), 3
(B), 7 (C) and 10 days after spinal cord injury (D). The levels
measured in animals with no
lesion were set as 100%. Twoway analysis of variance with
Student-Newman-Keuls post
hoc test was used to determine
statistical significance. *P <
0.05 (The color of asterisks indicates the statistically different
group(s)). n = 5/group per time
point. MIP-1α: Macrophage inflammatory protein 1-alpha; IL4: interleukin-4; IL-1β: interleukin-1beta; IL-2: interleukin-2;
IL-6: interleukin-6; RANTES:
regulated on activation, normal
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EGCG: epigallocatechin gallate.
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(Ge et al., 2013). Functional recovery after EGCG application could be attributed to the upregulation of GAP-43 protein level (Renno et al., 2015), and increased intrinsic levels
of BDNF and GDNF (Tian et al., 2013) after SCI.
Some of these effects that were observed in the combined
therapy of curcumin and EGCG contributed to the recovery
of SCI. The behavioral recovery in the combined therapy
of curcumin and EGCG was similar to application of curcumin alone; however, no synergistic effect was evident. In
more advanced tests, such as the flat beam test, the scores
were closer to the EGCG results. According to the publications (Khalatbary et al., 2010; Renno et al., 2014), the EGCG
therapy was more sensitive in mild to moderate injuries
affecting advanced locomotor settings. The advanced setting
of the flat beam test shows the ability of focusing on the
task and balancing without proper usage of the hindlimbs.
To be able to perform such a task, the animals must score
from 8 to 10 in the BBB open-field locomotor test. A score
of 1 indicates that to be able to balance on the flat, animals
must use forelimbs for movement. To reach scores higher
than 3, animals must be able to support their weight (above
score 10 in the BBB open-field locomotor test) and at least
partially coordinate hindlimb movements (scores 11-14 in
the open-field locomotor test). However, the ability to cross
the beam (score 3) does not directly correlate with the BBB
open-field locomotor test score. Animals able to hold the
beam with their hindlimbs from the sides can reach the target zone, even though in the BBB open-field locomotor test
they would not perform better than animals trying to step
on the top of the beam. Therefore, the flat beam test also reflects the motivation of the animal to reach the target zone,
even without stepping properly. The sensory function and
thermal hyperalgesia of the rats were assessed by the plantar
test, which measures withdrawal latency of the hindlimbs to
the thermal stimulus. The combined therapy of curcumin
and EGCG did not negatively affect thermal allodynia. To
report more about the effect of treatment on allodynia, studies on mechanical stimulus need to be added. The combined
therapy of curcumin and EGCG does affect the immune
response in a more discrete manner than monotherapy. We
observed decreased levels of IL-1β and IL-6, which are in
consistent with described anti-inflammatory properties of
both compounds (Khalatbary and Ahmadvand, 2011; Wang
et al., 2014; Gokce et al., 2016). In addition, with the exception of the 7th day after SCI, IL-4 levels were above the values
measured in saline treated animals at other time points. The
elevated level of MIP-1α in the early phase of SCI may function not only as a pro-inflammatory chemokine, but also as
a molecule to promote migration, growth and survival.
In conclusion, the combined therapy of curcumin and
EGCG for treatment of experimental SCI led to behavioral
recovery, even though not significantly superior to monotherapy. The combined therapy of curcumin and EGCG did
not influence growth factor response and spinal cord tissue
sparing, but it displayed a strong immunomodulatory response after SCI, and supported axonal sprouting and glial
scar reduction. Although the expected synergistic response
of this combined therapy was not achieved, different aspects
of tissue regeneration in severe SCI were understood.
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